Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Cannabis aandelen

8.264 Posts
Pagina: «« 1 ... 248 249 250 251 252 ... 414 »» | Laatste | Omlaag ↓
  1. Empros 20 november 2018 11:11
    quote:

    Teee schreef op 19 november 2018 21:50:

    [...]
    Dat is wel heel negatief
    Realistisch optimisme is wel gepast denk ik.

    Amerikaanse beurzen maken zich zorgen over de US & China handelsoorlog en beleggers dumpen tech.sector (FANG) en vluchten in obligaties. Eind deze maand kan de meeting Trump & Xi een oplossing brengen. US sleurt de Europese beurzen mee en bovendien doet de Brexit en de Italiaanse begroting ons de das om. Tracht het te zien als tijdelijke problemen.

    Met de uitzondering van enkele vanadium & uranium & goud-stocks zie ik niet veel groen.

    Zie het als een opportuniteit om bij te kopen of het beste dat je kan doen is dan ook "niets doen" en het "uitzitten" op voorwaarde dat de fundamentals van je investering onbetwist goed zijn! Bovendien geduld & LONG.
  2. forum rang 10 DeZwarteRidder 20 november 2018 14:09
    Highlights for the Third Quarter of 2018

    Record Company revenues of $2.3 million, a 281% increase year-over-year and a 50% increase quarter-over-quarter.
    Among industry-leading revenue per gram equivalent sold to patients of $10.67 per gram.
    Sales of high margin derivative products grew rapidly and represented 48% of total patient sales for the quarter, driving robust realized pricing.
    20% increase quarter-over-quarter in active registered patients to 4,820 as at September 30, 2018.
    Signed five-year supply agreement with Aphria Inc. (“Aphria”), to receive an aggregate of 175,000 kilogram equivalents of high-quality dried cannabis flower and crude cannabis oil at preferred wholesale pricing, commencing in May 2019.
    Strategic investment and three-year supply agreement with Natura Naturals Inc. (“Natura”), to receive up to 3,000 kilograms of high-quality cannabis flower per year at preferred wholesale pricing with deliveries to commence in December 2018.
    Launch of Symbl, Emblem’s first adult-use recreational cannabis brand.
    Signed supply agreements with the Alberta Gaming Cannabis Commission (“AGLC”) and the Ontario Cannabis Store (“OCS”). Fulfilled 100% of commitments to deliver cannabis products before September 30, 2018, which generated $0.8 million in revenues.
    Launched oral dose-metered spray, Atmosphere.
    Announced strategic partnership with GreenSpace Brands Inc. to develop and commercialize cannabidiol infused health and beauty products for the adult-use recreational market.
    Signed five-year supply agreement with and investment in Compass Cannabis Clinic to become a preferred cannabis supplier through its wholly owned subsidiary adult-use retail entity Starbuds Canada.
  3. wuiten001 20 november 2018 15:04
    Harvest One Completes Acquisition of Israeli-based Phytotech Therapeutics
    November 20, 2018
    Harvest One Cannabis Inc. (TSXV:HVT) ("Harvest One" or the "Company") is pleased to announce that it has completed its previously announced acquisition of 100% of Israeli-based Phytotech Therapeutics Ltd. ("Phytotech" or "PTL") from Australian-based MMJ Group Holdings Ltd. (formerly, MMJ Phytotech Limited) ("MMJ").
    In consideration for the acquisition of PTL, Harvest One paid C$1,000,000 in cash and 8,326,694 Harvest One common shares.
    Founded in 2014, Phytotech has developed advanced oral delivery formulations for cannabinoid-based prescription drugs and holds an exclusive worldwide licensing agreement with Yissum Research Development Company, the commercial arm of the University of Jerusalem, for a proprietary lipid nanotechnology.
    With the acquisition, Harvest One’s wholly-owned subsidiary Satipharm will gain access to advanced patents in favourable jurisdictions that can be used for further R&D and product development to aggressively pursue the rapidly evolving cannabis oils market.
    PTL was also responsible for administrating the successful clinical trials using Satipharm’s proprietary capsules. The Phase 1 clinical trials demonstrated the safety and high performance of the oral capsule technology, including the effective delivery profile of cannabidiol (“CBD”), while Phase 2 clinical trials were completed in 2017, returning favourable results in the treatment of pediatric epilepsy.
    “Harvest One’s acquisition of PTL gives all of the Company’s businesses access to valuable IP and capabilities that can be used to augment our health and wellness strategy as well as our medical offerings,” said Grant Froese, CEO of Harvest One. “This acquisition further demonstrates the global nature of Harvest One, now with a presence in Canada, the United States, the European Union and Israel".
    Due to the fact that MMJ is an insider and a related party of Harvest One, this transaction was considered a "related party transaction" as set out in Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions ("MI 61-101"). Harvest One relied on the exemption from the valuation requirements of MI 61-101 contained in section 5.5(a), and from minority approval requirements pursuant to section 5.7(a), due to the fact that the fair market value of the subject-matter of, and the consideration for, the transaction, did not exceed 25% of the market capitalization of Harvest One.
  4. W1S3 20 november 2018 15:20
    Mooie resultaten Emblem ! Hopelijk worden ze nu eindelijk opgemerkt door de markt. Ze verdienen het alvast.

    aan de "zwarte" : Rome is ook niet op 1 dag gebouw, Dit is een jong bedrijf, in een volledig nieuwe sector. Ik verwacht hier geen tientallen miljoenen omzet. Ik zie liever een kleinere omzet die elk jaar stevig vooruit gaat dan een grote omzet die elk jaar achteruit gaat.
  5. bogie 20 november 2018 17:25
    quote:

    DeZwarteRidder schreef op 20 november 2018 14:09:

    Highlights for the Third Quarter of 2018

    Record Company revenues of $2.3 million, a 281% increase year-over-year and a 50% increase quarter-over-quarter.
    Among industry-leading revenue per gram equivalent sold to patients of $10.67 per gram.
    Sales of high margin derivative products grew rapidly and represented 48% of total patient sales for the quarter, driving robust realized pricing.
    20% increase quarter-over-quarter in active registered patients to 4,820 as at September 30, 2018.
    Signed five-year supply agreement with Aphria Inc. (“Aphria”), to receive an aggregate of 175,000 kilogram equivalents of high-quality dried cannabis flower and crude cannabis oil at preferred wholesale pricing, commencing in May 2019.
    Strategic investment and three-year supply agreement with Natura Naturals Inc. (“Natura”), to receive up to 3,000 kilograms of high-quality cannabis flower per year at preferred wholesale pricing with deliveries to commence in December 2018.
    Launch of Symbl, Emblem’s first adult-use recreational cannabis brand.
    Signed supply agreements with the Alberta Gaming Cannabis Commission (“AGLC”) and the Ontario Cannabis Store (“OCS”). Fulfilled 100% of commitments to deliver cannabis products before September 30, 2018, which generated $0.8 million in revenues.
    Launched oral dose-metered spray, Atmosphere.
    Announced strategic partnership with GreenSpace Brands Inc. to develop and commercialize cannabidiol infused health and beauty products for the adult-use recreational market.
    Signed five-year supply agreement with and investment in Compass Cannabis Clinic to become a preferred cannabis supplier through its wholly owned subsidiary adult-use retail entity Starbuds Canada.
    Waarom hier reageren jij heb toch een wiet aandelen ?
  6. Empros 21 november 2018 11:12
    quote:

    Empros schreef op 20 november 2018 11:11:

    [...]

    Realistisch optimisme is wel gepast denk ik.

    Amerikaanse beurzen maken zich zorgen over de US & China handelsoorlog en beleggers dumpen tech.sector (FANG) en vluchten in obligaties. Eind deze maand kan de meeting Trump & Xi een oplossing brengen. US sleurt de Europese beurzen mee en bovendien doet de Brexit en de Italiaanse begroting ons de das om. Tracht het te zien als tijdelijke problemen.

    Met de uitzondering van enkele vanadium & uranium & goud-stocks zie ik niet veel groen.

    Zie het als een opportuniteit om bij te kopen of het beste dat je kan doen is dan ook "niets doen" en het "uitzitten" op voorwaarde dat de fundamentals van je investering onbetwist goed zijn! Bovendien geduld & LONG.
    Aurora Cannabis: Time To Buy The 'Blood In The Streets'

    seekingalpha.com/article/4223663-auro...
  7. wuiten001 21 november 2018 17:17
    Liever dagelijks een geloofwaardige plus dan vandaag dubbele cijfers en morgen dubbel rood. Het casino gegeven mag eruit. Liever stijgen op basis van cijfers, verkoop en/of prestaties dan mega winst op één dag en de dag erna mega verlies (al dan niet door toedoen van shorters). Zal ook de geloofwaardigheid van de markt ten goede komen en nieuwe investeerders over de brug trekken.
  8. RBkr 21 november 2018 17:35
    quote:

    wuiten001 schreef op 21 november 2018 17:17:

    Liever dagelijks een geloofwaardige plus dan vandaag dubbele cijfers en morgen dubbel rood. Het casino gegeven mag eruit. Liever stijgen op basis van cijfers, verkoop en/of prestaties dan mega winst op één dag en de dag erna mega verlies (al dan niet door toedoen van shorters). Zal ook de geloofwaardigheid van de markt ten goede komen en nieuwe investeerders over de brug trekken.
    Ja 100% met je eens. Maar die klappers naar beneden van de afgelopen weken een beetje recht trekken zou ik niet heel verkeerd vinden
8.264 Posts
Pagina: «« 1 ... 248 249 250 251 252 ... 414 »» | Laatste |Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 872,07 -0,22%
EUR/USD 1,0717 +0,18%
FTSE 100 8.089,17 +0,61%
Germany40^ 17.999,30 -0,49%
Gold spot 2.322,23 +0,26%
NY-Nasdaq Composite 15.712,75 +0,10%

Stijgers

UNILEV...
+4,45%
Fugro
+2,53%
Flow T...
+2,51%
Kendrion
+0,76%
SHELL PLC
+0,59%

Dalers

ADYEN NV
-11,32%
VIVORY...
-6,15%
BESI
-5,58%
WDP
-4,77%
IMCD
-1,91%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links